Last reviewed · How we verify
Intratumoral injection of ipilimumab and AS01b — Competitive Intelligence Brief
phase 1
Small molecule
Live · refreshed every 30 min
Target snapshot
Intratumoral injection of ipilimumab and AS01b (Intratumoral injection of ipilimumab and AS01b) — Universitair Ziekenhuis Brussel.
Comparator set
| Drug | Generic | Sponsor | Phase | Class | Target | Approval / PDUFA |
|---|---|---|---|---|---|---|
| Intratumoral injection of ipilimumab and AS01b TARGET | Intratumoral injection of ipilimumab and AS01b | Universitair Ziekenhuis Brussel | phase 1 |
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Patent timeline (forward window)
Sponsor landscape
Subscribe to ongoing alerts
Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:
- Intratumoral injection of ipilimumab and AS01b CI watch — RSS
- Intratumoral injection of ipilimumab and AS01b CI watch — Atom
- Intratumoral injection of ipilimumab and AS01b CI watch — JSON
- Intratumoral injection of ipilimumab and AS01b alone — RSS
Cite this brief
Drug Landscape (2026). Intratumoral injection of ipilimumab and AS01b — Competitive Intelligence Brief. https://druglandscape.com/ci/intratumoral-injection-of-ipilimumab-and-as01b. Accessed 2026-05-17.
Build your own brief
Pick any drug + add comparators:
https://druglandscape.com/ci/{slug}— auto-detected competitorshttps://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3— explicit comparators- Brand names auto-resolve:
/ci/keytruda→ 301 →/ci/pembrolizumab